Cardiovascular Safety and Bleeding Risk Associated with Nonsteroidal Anti-Inflammatory Medications in Patients with Cardiovascular Disease

[1] Schmidt M(2016)Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology Eur Heart J 37 1015-1023

[2] Lamberts M(2005)Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure Arch Intern Med 165 490-496

[3] Olsen AM(1993)A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure Arch Intern Med 153 477-484

[4] Fosbøll E(2008)Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials Eur J Heart Fail 10 1102-1107

[5] Niessner A(2000)Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N Engl J Med 343 1520-1528

[6] Tamargo J(2000)Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study JAMA 284 1247-1255

[7] Aw TJ(2005)Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery N Engl J Med 352 1081-1091

[8] Haas SJ(2005)Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 1092-1102

[9] Liew D(2006)Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials BMJ 332 1302-1308

[10] Krum H(2006)Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 JAMA 296 1633-1644

[1] Schmidt M(2016)Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology Eur Heart J 37 1015-1023

[2] Lamberts M(2005)Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure Arch Intern Med 165 490-496

[3] Olsen AM(1993)A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure Arch Intern Med 153 477-484

[4] Fosbøll E(2008)Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials Eur J Heart Fail 10 1102-1107

[5] Niessner A(2000)Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N Engl J Med 343 1520-1528

[6] Tamargo J(2000)Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study JAMA 284 1247-1255

[7] Aw TJ(2005)Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery N Engl J Med 352 1081-1091

[8] Haas SJ(2005)Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 1092-1102

[9] Liew D(2006)Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials BMJ 332 1302-1308

[10] Krum H(2006)Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 JAMA 296 1633-1644